(Q37707383)

22 August 2017

1 reference

title

Novel therapeutic targets for multiple myeloma (English)

1 reference

22 August 2017

Anuj Mahindra

1

1 reference

22 August 2017

Diana Cirstea

series ordinal

2

1 reference

22 August 2017

Noopur Raje

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

3

1 reference

22 August 2017

407-418

1 reference

Recent major improvement in long-term survival of younger patients with multiple myeloma

22 August 2017

1 reference

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

The AKT kinase is activated in multiple myeloma tumor cells

21 January 2018

1 reference

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

21 January 2018

1 reference

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

21 January 2018

1 reference

Identification and validation of novel therapeutic targets for multiple myeloma

21 January 2018

1 reference

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

21 January 2018

1 reference

Downstream effectors of oncogenic ras in multiple myeloma cells

21 January 2018

1 reference

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.

21 January 2018

1 reference

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

21 January 2018

1 reference

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

21 January 2018

1 reference

21 January 2018

mTOR and cancer therapy

1 reference

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

Defining the role of mTOR in cancer

21 January 2018

1 reference

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

21 January 2018

1 reference

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

21 January 2018

1 reference

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.

21 January 2018

1 reference

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

21 January 2018

1 reference

Molecular pathogenesis and a consequent classification of multiple myeloma

21 January 2018

1 reference

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

21 January 2018

1 reference

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

21 January 2018

1 reference

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

21 January 2018

1 reference

Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression

21 January 2018

1 reference

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

21 January 2018

1 reference

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

21 January 2018

1 reference

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

21 January 2018

1 reference

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

21 January 2018

1 reference

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model

21 January 2018

1 reference

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo

21 January 2018

1 reference

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

21 January 2018

1 reference

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

21 January 2018

1 reference

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.2

1 reference

22 August 2017

1 reference